Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics, has announced that CEO Dr. Deborah Birx will present at the 7th Annual Bacteriophage Therapy Summit in Boston, MA. The presentation is scheduled for Thursday, March 13, 2025, at 9:00am ET.

The company focuses on developing high-purity pathogen-specific bacteriophage therapeutics to address antibiotic-resistant and difficult-to-treat bacterial infections.

News Market Reaction

-6.50%

1 alert

-6.50% News Effect

On the day this news was published, ARMP declined 6.50%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LOS ANGELES, March 11, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 9:00am ET on Thursday, March 13, 2025 at the 7^th Annual Bacteriophage Therapy Summit, being held in Boston, MA.

For more information: https://bacteriophage-summit.com/

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic, including in-house phage-specific cGMP manufacturing to support full commercialization.

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-the-7th-annual-bacteriophage-therapy-summit-302392599.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When is Dr. Deborah Birx presenting at the 7th Annual Bacteriophage Therapy Summit for ARMP?

Dr. Birx will present on Thursday, March 13, 2025, at 9:00am ET in Boston, MA.

What type of therapeutics is Armata Pharmaceuticals (ARMP) developing?

Armata develops high-purity pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

Where will the 2025 Bacteriophage Therapy Summit featuring ARMP's presentation be held?

The 7th Annual Bacteriophage Therapy Summit will be held in Boston, MA.

What is ARMP's current development stage as a pharmaceutical company?

Armata Pharmaceuticals is a clinical-stage biotechnology company.